engleski

Comparative study of intravenous Azithromycin alone or intravenous treatment of pelvic inflammatory disease caused by Chlamydia trachomatis (Azitromicin u liječenju upalne bolesti male zdjelice)

A total of 61 female patients over 18 years of age with diagnosed pelvic inflammatory disease caused by Chlamydia trachomatis were examined. The patients were randomized to receive either azithromycin 1 x 500 mg iv for 5 days (30 patients) or 1 x 500 mg iv for 2 days followed by 1 x 500 mg po for the next 3 days (31 patients). Clinical and bacteriological efficacy and tolerability of therapy were assessed 3-4 weeks after completion of therapy. Clinical cure (19/30 : 18/31 ; p=0.87) and chlamydial eradication (25/30 ; 24/31 ; p=0.79) were not significantly different with regards to the route of drug administration. No side effects were recorded.

Azithromycin; pelvic inflammatory disease

nije evidentirano